Search

Your search keyword '"Zahrani MA"' showing total 4 results
Start Over Author "Zahrani MA" Topic hematopoietic stem cell transplantation
Sorry, I don't understand your search. ×
4 results on '"Zahrani MA"'

1. Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT.

Author

Giebel S, Labopin M, Socié G, Aljurf M, Salmenniemi U, Labussière-Wallet H, Srour M, Kröger N, Zahrani MA, Lioure B, Reményi P, Arat M, Bourhis JH, Helbig G, Tbakhi A, Forcade E, Huynh A, Brissot E, Spirydonidis A, Savani BN, Peric Z, Nagler A, and Mohty M

Subjects
Adult, Humans, Whole-Body Irradiation adverse effects, Retrospective Studies, Transplantation, Homologous adverse effects, Cyclophosphamide therapeutic use, Acute Disease, Recurrence, Transplantation Conditioning adverse effects, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma complications, Hematopoietic Stem Cell Transplantation adverse effects, Leukemia, Myeloid, Acute complications, Graft vs Host Disease etiology
Abstract

In this registry-based study we retrospectively compared outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) for adult patients with acute lymphoblastic leukemia (ALL) following conditioning with total body irradiation (TBI) combined with either cyclophosphamide (Cy) or fludarabine (Flu). TBI 12 Gy + Cy was used in 2105 cases while TBI 12 Gy + Flu was administered to 150 patients in first or second complete remission. In a multivariate model adjusted for other prognostic factors, TBI/Cy conditioning was associated with a reduced risk of relapse (HR = 0.69, p = 0.049) and increased risk of grade 2-4 acute graft-versus-host disease (GVHD, HR = 1.57, p = 0.03) without significant effect on other transplantation outcomes. In a matched-pair analysis the use of TBI/Cy as compared to TBI/Flu was associated with a significantly reduced rate of relapse (18% vs. 30% at 2 years, p = 0.015) without significant effect on non-relapse mortality, GVHD and survival. We conclude that the use of myeloablative TBI/Cy as conditioning prior to allo-HCT for adult patients with ALL in complete remission is associated with lower risk of relapse rate compared to TBI/Flu and therefore should probably be considered a preferable regimen., (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)

Published
2023
Full Text
View/download PDF

2. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.

Author

Drozd-Sokolowska J, Gras L, Zinger N, Zahrani MA, Passweg J, Byrne J, Ho A, Huang XJ, Kröger N, Mayer J, Russo D, De Becker A, Tbakhi A, Stamatoullas A, Valerius T, Hayden P, McLornan DP, Onida F, Scheid C, Robin M, and Yakoub-Agha I

Subjects
Humans, Retrospective Studies, Transplantation Conditioning, Myelodysplastic Syndromes therapy, Hematopoietic Stem Cell Transplantation, Neoplasms
Published
2023
Full Text
View/download PDF

3. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey.

Author

Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Zahrani MA, Apperley J, Berceanu A, Bofarull RM, Calbacho M, Ciceri F, Lopez-Corral L, Crippa C, Fox ML, Grassi A, Jimenez MJ, Demir SK, Kwon M, Llamas CV, Lorenzo JLL, Mielke S, Orchard K, Porras RP, Vallisa D, Xhaard A, Knelange NS, Cedillo A, Kröger N, Piñana JL, and Styczynski J

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, COVID-19 virology, Child, Child, Preschool, Female, Follow-Up Studies, Hematologic Neoplasms epidemiology, Hematologic Neoplasms virology, Humans, Infant, Male, Middle Aged, Prognosis, Prospective Studies, Survival Rate, Transplantation, Homologous, Young Adult, COVID-19 complications, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation methods, SARS-CoV-2 isolation & purification
Abstract

This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0-80.3) for allogeneic, and 60.6 years (7.7-81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2-292.7) in allogeneic and 24.6 months (-0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age (p = 0.02), need for ICU (p < 0.0001) and moderate/high immunodeficiency index (p = 0.04) increased the risk while better performance status (p = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19., (© 2021. The Author(s).)

Published
2021
Full Text
View/download PDF

4. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

Author

Carlos Vallejo Llamas, Mohsen Al Zahrani, Per Ljungman, Kim Orchard, María J. Jiménez, María Calbacho, Beatriz Aguado, Jose Luis Lopez Lorenzo, Safiye Koçulu Demir, Rafael de la Cámara, Aliénor Xhaard, Rocio Parody Porras, Maria Laura Fox, Rodrigo Martino Bofarull, Daniele Vallisa, José Luis Piñana, Gloria Tridello, Mi Kwon, Angel Cedillo, Anna De Grassi, Nina Knelange, Jane F. Apperley, Malgorzata Mikulska, Jan Styczyński, Stephan Mielke, Nicolaus Kröger, Lucía López-Corral, Fabio Ciceri, Claudia Crippa, Ana Berceanu, National Institute for Health Research (UK), Ljungman, P., de la Camara, R., Mikulska, M., Tridello, G., Aguado, B., Zahrani, M. A., Apperley, J., Berceanu, A., Bofarull, R. M., Calbacho, M., Ciceri, F., Lopez-Corral, L., Crippa, C., Fox, M. L., Grassi, A., Jimenez, M. -J., Demir, S. K., Kwon, M., Llamas, C. V., Lorenzo, J. L. L., Mielke, S., Orchard, K., Porras, R. P., Vallisa, D., Xhaard, A., Knelange, N. S., Cedillo, A., Kroger, N., Pinana, J. L., Styczynski, J., Institut Català de la Salut, [Ljungman P] Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, Stockholm, Sweden. Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. [de la Camara R] Department of Hematology, Hospital de la Princesa, Madrid, Spain. [Mikulska M] Division of Infectious Diseases, University of Genoa and Ospedale Policlinico San Martino, Genova, Italy. [Tridello G] Pediatric Hematology Oncology, Verona, Italy. [Aguado B] Department of Hematology, Hospital de la Princesa, Madrid, Spain. [Zahrani MA] King Abdul – Aziz Medical City, Riyadh, Saudi Arabia. [Fox ML] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Male, Cancer Research, medicine.medical_treatment, Hematopoietic stem cell transplantation, Stem cells, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Medicine, Prospective Studies, Young adult, Prospective cohort study, Child, Immunodeficiency, COVID-19 (Malaltia) - Complicacions, Aged, 80 and over, Hematopoietic Stem Cell Transplantation, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Immunosuppression, Hematology, Middle Aged, Prognosis, Survival Rate, Oncology, Child, Preschool, Hematologic Neoplasms, Infectious diseases, Female, Cèl·lules mare, terapéutica::terapia biológica::tratamientos basados en células y tejidos::trasplante de células::trasplante de células madre::trasplante de células madre hematopoyéticas [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Haematological diseases, Adult, medicine.medical_specialty, Adolescent, Article, Young Adult, Internal medicine, Mortalitat, Humans, Transplantation, Homologous, Mortality, Survival rate, Aged, Performance status, Cèl·lules mare hematopoètiques - Trasplantació, business.industry, SARS-CoV-2, Infant, COVID-19, técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], medicine.disease, Transplantation, Sang - Malalties, Therapeutics::Biological Therapy::Cell- and Tissue-Based Therapy::Cell Transplantation::Stem Cell Transplantation::Hematopoietic Stem Cell Transplantation [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], business, Follow-Up Studies
Abstract

© The Author(s) 2021., This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0–80.3) for allogeneic, and 60.6 years (7.7–81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2–292.7) in allogeneic and 24.6 months (−0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age (p = 0.02), need for ICU (p < 0.0001) and moderate/high immunodeficiency index (p = 0.04) increased the risk while better performance status (p = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19., JA acknowledges the support of the UK NIHR Imperial College Biomedical Research Centre.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results